BioSkryb Genomics launched ResolveSEQ MRD, a service that enhances the analysis of minimal residual disease (MRD) in hematological malignancies. This service integrates with existing flow cytometry methods to provide single-cell genome and transcriptome characterization. The goal is to offer deeper biological insights to advance precision oncology.
This development is crucial for advancing cancer research and treatment. Current MRD tests can detect residual cancer cells but don’t explain why these cells resist treatment and cause disease persistence. ResolveSEQ MRD addresses this limitation by providing detailed genomic and transcriptomic data from individual MRD cells. This allows researchers to pinpoint the specific reasons why certain therapies fail and potentially personalize treatments based on the unique biological features of persistent disease. This level of analysis can significantly improve patient outcomes by guiding clinicians towards the most effective treatment strategies while minimizing exposure to unnecessary and potentially harmful therapies.
ResolveSEQ MRD provides paired genome and transcriptome data from individual MRD cells. BioSkryb Genomics is also launching a Certified Service Provider Program to expand access to its single-cell multiomics technologies. This program enables trained partners to utilize BioSkryb’s products and services within their own labs, providing end-to-end solutions for customers. Some providers will also be able to operate within regulated environments, broadening access to the technology and reducing costs and turnaround times for researchers.
This advancement positions BioSkryb Genomics as a leader in the evolving landscape of precision oncology. ResolveSEQ MRD has the potential to revolutionize MRD analysis, moving beyond mere detection to provide actionable insights for treatment optimization. The availability of this technology through the CSP program will further accelerate the development of novel therapeutics by fostering a deeper understanding of treatment resistance mechanisms, ultimately leading to improved patient outcomes. This enhanced understanding of disease persistence could lead to the development of more targeted and effective therapies for hematological malignancies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
